Lutris Pharma to Present Updated Data on LUT014 Gel at EADV Congress
News related to:Lutris Pharma · 1 min read
TEL AVIV, Israel, Sept. 16, 2026 /CourierPR/ -- Lutris Pharma, a clinical-stage biopharmaceutical company, will present updated data from its Phase 2 trial of LUT014 gel at the 35th European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, from September 30 to October 3, 2026.
The company’s lead compound, LUT014, is a novel topical B-Raf inhibitor designed to reduce or prevent the worsening of dermatological toxicities caused by anti-cancer drugs that target the MAPK pathway. These drugs, such as EGFR inhibitors, can lead to adverse reactions, including a papulopustular skin rash, commonly known as acneiform lesions. This rash can significantly impact the quality of life and adherence to therapy for patients.
LUT014 works by harnessing the paradoxical effect of B-Raf inhibitors. When a MAPK inhibitor that acts upstream of B-Raf is used for cancer treatment, the MAPK pathway reduces or stops signaling, leading to cell death. However, this can also affect normal cells, such as those in the skin, causing side effects like the acneiform rash. LUT014 is formulated as a gel and is applied topically to the affected areas of the skin, aiming to mitigate these side effects.
The presentation is scheduled for Friday, October 2, 2026, from 11:25 to 11:35 am CET in Hall N.
The Phase 2 trial involved metastatic colorectal cancer patients who were experiencing EGFR inhibitor-induced acneiform lesions. The results have shown favorable safety and clinical benefit, indicating that LUT014 can effectively reduce or prevent the worsening of these dermatological toxicities.
Lutris Pharma’s mission is to improve the quality of life and drug adherence for patients treated with anti-cancer therapies by mitigating dermatological toxicities. The company’s key asset, LUT014, is a proprietary, first-in-class, small molecule, topical B-Raf inhibitor designed to address the paradoxical effects of MAPK inhibitors.
The presentation at the EADV Congress is expected to provide valuable insights into the potential of LUT014 in managing dermatological toxicities associated with anti-cancer drugs, potentially enhancing patient outcomes and adherence to treatment regimens.